Astrana Health, Inc. Reports Third Quarter 2025 Results
Financial Performance: Astrana Health, Inc. reported total revenue of $956 million for Q3 2025, a 100% increase year-over-year, with adjusted EBITDA of $68.5 million, also at the higher end of guidance.
Acquisition and Integration: The company successfully closed the acquisition of Prospect Health, with its standalone performance exceeding expectations, and is progressing well with integration to enhance operational capabilities.
Guidance Update: Astrana updated its full-year 2025 guidance to reflect delays in full-risk contract transitions, projecting total revenue between $3.1 billion and $3.18 billion and adjusted EBITDA between $200 million and $210 million.
Strategic Partnerships: The company announced partnerships with Intermountain Health and a provider group in Southern California to expand access to coordinated care and enhance healthcare delivery across key markets.
Trade with 70% Backtested Accuracy
Analyst Views on ASTH
About ASTH
About the author
Astrana Health Stock Plummets 22% Amid Medicare Payment Concerns
- Significant Stock Drop: Astrana Health Inc. shares fell approximately 22% to close at $21.48 on Tuesday, primarily due to CMS's proposed 0.09% payment growth for Medicare Advantage in 2027, indicating weak payment growth that could impact future revenues.
- High Revenue Dependency: Analysts noted that Medicare accounts for about 61% of Astrana Health's revenue, and despite the sharp decline, the stock's drop was more severe than peers like Agilon Health and Alignment Healthcare, which fell around 10% and 12%, respectively, reflecting greater market concerns about Astrana.
- Differentiated Risk Adjustment Practices: Analyst William Blair highlighted that Astrana Health's risk adjustment practices differ from larger payers, relying on direct patient care rather than audio-only visits or standalone chart reviews, resulting in lower exposure to the risk score impacts proposed by CMS.
- Long-Term Value Potential: Despite short-term pressures, analysts believe that CMS's proposals could enhance the company's long-term value, as payers will need to rely on fully delegated care delivery partners to manage patients and costs, potentially leading to more delegated contract agreements in 2027 and beyond.
Astrana Health to Present at 2026 JP Morgan Healthcare Conference, Showcasing AI Innovations
- Conference Participation: Astrana Health will present at the J.P. Morgan Healthcare Conference on January 12, 2026, in San Francisco, showcasing its latest advancements in healthcare technology, which is expected to attract investor and industry attention, thereby enhancing the company's visibility in the healthcare sector.
- Technology-Driven: As a physician-centric, AI-powered healthcare company, Astrana Health supports over 20,000 providers and 1.6 million patients through its proprietary technology platform and aligned provider networks, driving the implementation of value-based care that enhances patient experiences and outcomes.
- Market Positioning: Astrana Health's business model integrates scalable care delivery infrastructure with proactive preventive care capabilities, aiming to improve the overall value of the healthcare system and strengthen the company's strategic position in a competitive healthcare market.
- Future Outlook: By participating in key industry conferences, Astrana Health not only showcases its technological innovations but also paves the way for future investment opportunities, further solidifying its leadership position in the healthcare sector.
Astrana Health to Present at J.P. Morgan 2026 Healthcare Conference, Showcasing AI-Driven Care Solutions
- Leadership Participation: Astrana Health's leadership will present at the J.P. Morgan Healthcare Conference on January 12, 2026, in San Francisco, showcasing their latest advancements in healthcare technology, which is expected to attract investor and industry attention.
- Technology-Driven Care: As a physician-centric company, Astrana Health supports over 20,000 providers and 1.6 million patients through its proprietary technology platform and aligned provider networks, driving the implementation of value-based care that enhances patient experiences and outcomes.
- Market Impact: Astrana Health's participation not only highlights its innovative capabilities in the healthcare sector but also has the potential to strengthen its position in a competitive market, attracting more partners and investments.
- Future Outlook: By showcasing its AI-driven care solutions at the conference, Astrana Health aims to further promote transformative changes in the healthcare system, leading to higher medical value and better patient outcomes.
ASTH Stock Analysis: 52-Week Low at $20.12 with Current Price at $27.40
- Stock Fluctuation: ASTH's 52-week low is $20.12, with a high of $39.97, and the current trading price at $27.40 indicates stability within this range, which may influence investor confidence and market expectations.
- Market Performance: The current price of $27.40 shows a significant gap from the 52-week high, suggesting a cautious market sentiment regarding ASTH's future performance, potentially impacting its fundraising capabilities and investor appeal.
- Technical Indicators: ASTH's stock price has crossed above the 200-day moving average, which may attract the attention of technical analysis investors, thereby influencing short-term trading strategies and market liquidity.
- Investor Sentiment: Although the current stock price is positioned in the middle of the 52-week range, investor sentiment towards ASTH's future performance remains cautious, which could lead to increased market volatility.
New CMS Accountable Care Model Expected to Benefit Value-Based Care Providers
New ACO Model Introduction: CMS has announced the Long-term Enhanced ACO Design (LEAD) model, a 10-year voluntary pilot program starting in 2027, aimed at improving value-based care for healthcare providers.
Improvements Over Previous Model: LEAD addresses financial and administrative challenges faced by providers, offering enhanced cash flow payments and tools to better meet patient needs, particularly for high-needs patients.
Positive Industry Reaction: Jefferies has responded favorably to the LEAD model, indicating it provides future flexibility and stability for value-based care within Medicare fee-for-service.
Supporting Companies: Companies like Astrana Health, agilon health, and Privia Health Group are involved in supporting ACOs, with recent developments in their financial standings and market positions.
Jefferies Keeps Buy Rating on Astrana Health, Reduces Price Target to $37
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, fostering a collaborative environment for sharing market intelligence.
Market Success: Traders utilize Benzinga Pro's resources to gain a competitive edge and improve their chances of winning in the markets daily.
Astrana Health Stock Plummets 22% Amid Medicare Payment Concerns
- Significant Stock Drop: Astrana Health Inc. shares fell approximately 22% to close at $21.48 on Tuesday, primarily due to CMS's proposed 0.09% payment growth for Medicare Advantage in 2027, indicating weak payment growth that could impact future revenues.
- High Revenue Dependency: Analysts noted that Medicare accounts for about 61% of Astrana Health's revenue, and despite the sharp decline, the stock's drop was more severe than peers like Agilon Health and Alignment Healthcare, which fell around 10% and 12%, respectively, reflecting greater market concerns about Astrana.
- Differentiated Risk Adjustment Practices: Analyst William Blair highlighted that Astrana Health's risk adjustment practices differ from larger payers, relying on direct patient care rather than audio-only visits or standalone chart reviews, resulting in lower exposure to the risk score impacts proposed by CMS.
- Long-Term Value Potential: Despite short-term pressures, analysts believe that CMS's proposals could enhance the company's long-term value, as payers will need to rely on fully delegated care delivery partners to manage patients and costs, potentially leading to more delegated contract agreements in 2027 and beyond.
Astrana Health to Present at 2026 JP Morgan Healthcare Conference, Showcasing AI Innovations
- Conference Participation: Astrana Health will present at the J.P. Morgan Healthcare Conference on January 12, 2026, in San Francisco, showcasing its latest advancements in healthcare technology, which is expected to attract investor and industry attention, thereby enhancing the company's visibility in the healthcare sector.
- Technology-Driven: As a physician-centric, AI-powered healthcare company, Astrana Health supports over 20,000 providers and 1.6 million patients through its proprietary technology platform and aligned provider networks, driving the implementation of value-based care that enhances patient experiences and outcomes.
- Market Positioning: Astrana Health's business model integrates scalable care delivery infrastructure with proactive preventive care capabilities, aiming to improve the overall value of the healthcare system and strengthen the company's strategic position in a competitive healthcare market.
- Future Outlook: By participating in key industry conferences, Astrana Health not only showcases its technological innovations but also paves the way for future investment opportunities, further solidifying its leadership position in the healthcare sector.
Astrana Health to Present at J.P. Morgan 2026 Healthcare Conference, Showcasing AI-Driven Care Solutions
- Leadership Participation: Astrana Health's leadership will present at the J.P. Morgan Healthcare Conference on January 12, 2026, in San Francisco, showcasing their latest advancements in healthcare technology, which is expected to attract investor and industry attention.
- Technology-Driven Care: As a physician-centric company, Astrana Health supports over 20,000 providers and 1.6 million patients through its proprietary technology platform and aligned provider networks, driving the implementation of value-based care that enhances patient experiences and outcomes.
- Market Impact: Astrana Health's participation not only highlights its innovative capabilities in the healthcare sector but also has the potential to strengthen its position in a competitive market, attracting more partners and investments.
- Future Outlook: By showcasing its AI-driven care solutions at the conference, Astrana Health aims to further promote transformative changes in the healthcare system, leading to higher medical value and better patient outcomes.
ASTH Stock Analysis: 52-Week Low at $20.12 with Current Price at $27.40
- Stock Fluctuation: ASTH's 52-week low is $20.12, with a high of $39.97, and the current trading price at $27.40 indicates stability within this range, which may influence investor confidence and market expectations.
- Market Performance: The current price of $27.40 shows a significant gap from the 52-week high, suggesting a cautious market sentiment regarding ASTH's future performance, potentially impacting its fundraising capabilities and investor appeal.
- Technical Indicators: ASTH's stock price has crossed above the 200-day moving average, which may attract the attention of technical analysis investors, thereby influencing short-term trading strategies and market liquidity.
- Investor Sentiment: Although the current stock price is positioned in the middle of the 52-week range, investor sentiment towards ASTH's future performance remains cautious, which could lead to increased market volatility.
New CMS Accountable Care Model Expected to Benefit Value-Based Care Providers
New ACO Model Introduction: CMS has announced the Long-term Enhanced ACO Design (LEAD) model, a 10-year voluntary pilot program starting in 2027, aimed at improving value-based care for healthcare providers.
Improvements Over Previous Model: LEAD addresses financial and administrative challenges faced by providers, offering enhanced cash flow payments and tools to better meet patient needs, particularly for high-needs patients.
Positive Industry Reaction: Jefferies has responded favorably to the LEAD model, indicating it provides future flexibility and stability for value-based care within Medicare fee-for-service.
Supporting Companies: Companies like Astrana Health, agilon health, and Privia Health Group are involved in supporting ACOs, with recent developments in their financial standings and market positions.
Jefferies Keeps Buy Rating on Astrana Health, Reduces Price Target to $37
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, fostering a collaborative environment for sharing market intelligence.
Market Success: Traders utilize Benzinga Pro's resources to gain a competitive edge and improve their chances of winning in the markets daily.
